[1]
|
Gattermann, N. (2009) The Treatment of Secondary Hemochromatosis. Deutsches Arzteblatt International, 106, 499-504. https://doi.org/10.3238/arztebl.2009.0499
|
[2]
|
Crawford, D.H.G., Ramm, G.A., Bridle, K.R., et al. (2023) Clinical Practice Guidelines on Hemochromatosis: Asian Pacific Association for the Study of the Liver. Hepatology International, 17, 522-541. https://doi.org/10.1007/s12072-023-10510-3
|
[3]
|
Hsu, C.C., Senussi, N.H., Fertrin, K.Y., et al. (2022) Iron Overload Disorders. Hepatology Communications, 6, 1842-1854. https://doi.org/10.1002/hep4.2012
|
[4]
|
Pinyopornpanish, K., Tantiworawit, A., Leerapun, A., et al. (2023) Secondary Iron Overload and the Liver: A Comprehensive Review. Journal of Clinical and Translational Hepatology, 11, 932-941.
|
[5]
|
Malcovati, L., Porta, M.G., Pascutto, C., et al. (2005) Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 7594-7603. https://doi.org/10.1200/JCO.2005.01.7038
|
[6]
|
王琳. 活血化痰配伍对高脂血症合并铁代谢异常小鼠的保护效应研究[D]: [硕士学位论文]. 兰州: 甘肃中医药大学中西医结合临床, 2016.
|
[7]
|
Bacon, B.R., Adams, P.C., Kowdley, K.V., et al. (2011) Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), 54, 328-343. https://doi.org/10.1002/hep.24330
|
[8]
|
中华医学会, 中华医学会杂志社, 中华医学会消化病学分会. 酒精性肝病基层诊疗指南(2019年) [J]. 中华全科医师杂志, 2020, 19(11): 990-996.
|
[9]
|
薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227.
|
[10]
|
Dongiovanni, P., Lanti, C., Gatti, S., et al. (2015) High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload. PLOS ONE, 10, e0116855. https://doi.org/10.1371/journal.pone.0116855
|
[11]
|
Horton, J.D., Cohen, J.C. and Hobbs, H.H. (2009) PCSK9: A Convertase That Coordinates LDL Catabolism. Journal of Lipid Research, 50, S172-S177. https://doi.org/10.1194/jlr.R800091-JLR200
|
[12]
|
Abifadel, M., Varret, M., Rabès, J.P., et al. (2003) Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia. Nature Genetics, 34, 154-156. https://doi.org/10.1038/ng1161
|
[13]
|
Cunningham, D., Danley, D.E., Geoghegan, K.F., et al. (2007) Structural and Biophysical Studies of PCSK9 and Its Mutants Linked to Familial Hypercholesterolemia. Nature Structural & Molecular Biology, 14, 413-419. https://doi.org/10.1038/nsmb1235
|
[14]
|
封思琴, 王一斐, 陈沛沛. PCSK9抑制剂多效性的研究进展[J]. 中华心血管病杂志, 2022, 50(3): 313-318.
|
[15]
|
Varret, M., Rabès, J.P., Saint-Jore, B., et al. (1999) A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32. American Journal of Human Genetics, 64, 1378-1387. https://doi.org/10.1086/302370
|
[16]
|
中华医学会心血管病学分会动脉粥样硬化及冠心病学组, 中华心血管病杂志编辑委员会. 家族性高胆固醇血症筛查与诊治中国专家共识[J]. 中华心血管病杂志, 2018, 46(2): 99-103.
|
[17]
|
Hori, M., Ohta, N., Takahashi, A., et al. (2019) Impact of LDLR and PCSK9 Pathogenic Variants in Japanese Heterozygous Familial Hypercholesterolemia Patients. Atherosclerosis, 289, 101-108. https://doi.org/10.1016/j.atherosclerosis.2019.08.004
|
[18]
|
彭彦人, 陈国军, 郑华. PCSK9抑制剂对不同基线水平的甘油三酯降低效果不同[J]. 南方医科大学学报, 2020, 40(8): 1141-1147.
|
[19]
|
Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722. https://doi.org/10.1056/NEJMoa1615664
|
[20]
|
Peng, Y., Guo, D., Jiang, S., et al. (2022) Application of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Evolocumab, in Patients with Severe Hypertriglyceridemia. Chinese Medical Journal, 135, 730-731. https://doi.org/10.1097/CM9.0000000000001896
|
[21]
|
Lohoff, F.W., Sorcher, J.L., Rosen, A.D., et al. (2018) Methylomic Profiling and Replication Implicates Deregulation of PCSK9 in Alcohol Use Disorder. Molecular Psychiatry, 23, 1900-1910. https://doi.org/10.1038/mp.2017.168
|
[22]
|
Lee, J.S., Mukhopadhyay, P., Matyas, C., et al. (2019) PCSK9 Inhibition as a Novel Therapeutic Target for Alcoholic Liver Disease. Scientific Reports, 9, Article No. 17167. https://doi.org/10.1038/s41598-019-53603-6
|